ID   XG-7
AC   CVCL_A772
SY   XG7; XG 7
DR   ArrayExpress; E-TABM-1088
DR   Cosmic; 2081414
DR   Cosmic; 2367269
DR   IARC_TP53; 28519
DR   Wikidata; Q54994716
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8204890;
RX   PubMed=10557056;
RX   PubMed=10936422;
RX   PubMed=11429052;
RX   PubMed=16956823;
RX   PubMed=17229644;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=21173094;
RX   PubMed=30545397;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   Characteristics: Produces IgA kappa.
CC   Characteristics: IL6 dependent.
CC   HLA typing: A*02:01,24; B*07,40; C*02:02,07 (Direct_author_submission).
CC   Sequence variation: KRAS p.Gly12Cys (c.34G>T) (ClinVar=VCV000012578) (PubMed=21173094).
CC   Sequence variation: Has no TP53 mutation (PubMed=21173094).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis.
CC   Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C.
CC   Derived from sampling site: Peripheral blood.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-07-20; Version: 15
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8204890; DOI=10.1182/blood.V83.12.3654.3654;
RA   Zhang X.-G., Gaillard J.-P., Robillard N., Lu Z.-Y., Gu Z.-J.,
RA   Jourdan M., Boiron J.-M., Bataille R., Klein B.;
RT   "Reproducible obtaining of human myeloma cell lines as a model for
RT   tumor stem cell study in human multiple myeloma.";
RL   Blood 83:3654-3663(1994).
//
RX   PubMed=10557056; DOI=10.1038/sj.leu.2401563;
RA   Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A.,
RA   Shimizu S., Taniwaki M., Ueda R.;
RT   "Detection of MUM1/IRF4-IgH fusion in multiple myeloma.";
RL   Leukemia 13:1812-1816(1999).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11429052; DOI=10.1111/j.1349-7006.2001.tb01142.x;
RA   Hanamura I., Iida S., Akano Y., Hayami Y., Kato M., Miura K.,
RA   Harada S., Banno S., Wakita A., Kiyoi H., Naoe T., Shimizu S.,
RA   Sonta S.-I., Nitta M., Taniwaki M., Ueda R.;
RT   "Ectopic expression of MAFB gene in human myeloma cells carrying
RT   (14;20)(q32;q11) chromosomal translocations.";
RL   Jpn. J. Cancer Res. 92:638-644(2001).
//
RX   PubMed=16956823;
RA   Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L.,
RA   Moreau P., Amiot M., Pellat-Deceunynck C.;
RT   "The phenotype of normal, reactive and malignant plasma cells.
RT   Identification of 'many and multiple myelomas' and of new targets for
RT   myeloma therapy.";
RL   Haematologica 91:1234-1240(2006).
//
RX   PubMed=17229644; DOI=10.3324/haematol.10300;
RA   Sanda T., Iida S., Kayukawa S., Ueda R.;
RT   "Induction of class II major histocompatibility complex expression in
RT   human multiple myeloma cells by retinoid.";
RL   Haematologica 92:115-120(2007).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T., Ahmann G., Mancini C.,
RA   Brents L.A., Kumar S., Greipp P., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M., Valdez R., Trent J.M., Stewart A.K.,
RA   Carpten J., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=21173094; DOI=10.3324/haematol.2010.033456;
RA   Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D.,
RA   Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M.,
RA   Pellat-Deceunynck C.;
RT   "A high-risk signature for patients with multiple myeloma established
RT   from the molecular classification of human myeloma cell lines.";
RL   Haematologica 96:574-582(2011).
//
RX   PubMed=30545397; DOI=10.1186/s13045-018-0679-0;
RA   Tessoulin B., Moreau-Aubry A., Descamps G., Gomez-Bougie P., Maiga S.,
RA   Gaignard A., Chiron D., Menoret E., Le Gouill S., Moreau P., Amiot M.,
RA   Pellat-Deceunynck C.;
RT   "Whole-exon sequencing of human myeloma cell lines shows mutations
RT   related to myeloma patients at relapse with major hits in the DNA
RT   regulation and repair pathways.";
RL   J. Hematol. Oncol. 11:137-137(2018).
//